 |
|
|
| |
Faldaprevir Plus Pegylated Interferon
α-2a/Ribavirin in HIV/HCV Co infection: STARTVerso4
|
| |
| |
Reported by Jules Levin
23rd Conference of the Asian Pacific Association for the Study of the Liver (APASL), March 12-15, 2014, Brisbane, Australia
Douglas Dieterich1, Cristina Tural2, Mark Nelson3, Keikawus Arasteh4, Vicente Soriano5, Josep Guardiola6, Sanjay Bhagani7, Jurgen K Rockstroh8, Jerry O Stern9, Anne-Marie Quinson9, on behalf of the STARTVerso4 Study Group
1Mount Sinai Medical Center, New York, NY, USA; 2Hospital Universitari Germans Trias i Pujol, Barcelona, Spain; 3Chelsea and Westminster Hospital, London, UK; 4EPIMED / Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany; 5Hospital Carlos III, Madrid, Spain; 6Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 7The Royal Free Hospital, London, UK; 8University of Bonn, Bonn, Germany; 9Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
|
| |
|
|
|
|
|
